Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2-3
|
pubmed:dateCreated |
1986-2-18
|
pubmed:abstractText |
Total and low density lipoprotein cholesterol concentration reduction in patients with markedly increased levels of these substances, leads to a decline in the incidence of myocardial infarction and death. A unique cholesterol-rich lipoprotein, lipoprotein Lp(a), has been identified which not only can be confused with low density lipoproteins, but has also been associated with premature cardiovascular disease. Using the cholesterol-lowering drugs neomycin and niacin in 14 type II hyperlipoproteinemic subjects, we determined the effect of lipid-lowering therapy on lipoprotein Lp(a) concentrations. Neomycin (2g/day) reduced low density lipoprotein cholesterol and lipoprotein Lp(a) concentrations by 23% and 24%, respectively. Combination therapy with neomycin (2 g/day) and niacin (3 g/day) induced a 48% decline in low density lipoprotein cholesterol levels and a 45% reduction in the concentration of lipoprotein Lp(a). These changes in lipoprotein Lp(a) levels were associated with a striking decline in the intensity of the slow pre-beta-lipoprotein fraction determined Lp(a) by lipoprotein electrophoresis. This slow pre-beta-lipoprotein fraction contained Lp(a) determined by immunofixation. These observations indicate that lipoprotein Lp(a) concentrations can be altered pharmacologically and that the progression of cardiovascular disease may be altered through changes in lipoprotein (a) levels.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol, LDL,
http://linkedlifedata.com/resource/pubmed/chemical/Lipids,
http://linkedlifedata.com/resource/pubmed/chemical/Lipoprotein(a),
http://linkedlifedata.com/resource/pubmed/chemical/Lipoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Lipoproteins, VLDL,
http://linkedlifedata.com/resource/pubmed/chemical/Neomycin,
http://linkedlifedata.com/resource/pubmed/chemical/Niacin
|
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
0021-9150
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
57
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
293-301
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:2935163-Adult,
pubmed-meshheading:2935163-Aged,
pubmed-meshheading:2935163-Cardiovascular Diseases,
pubmed-meshheading:2935163-Cholesterol, LDL,
pubmed-meshheading:2935163-Female,
pubmed-meshheading:2935163-Humans,
pubmed-meshheading:2935163-Hyperlipoproteinemia Type II,
pubmed-meshheading:2935163-Lipids,
pubmed-meshheading:2935163-Lipoprotein(a),
pubmed-meshheading:2935163-Lipoproteins,
pubmed-meshheading:2935163-Lipoproteins, VLDL,
pubmed-meshheading:2935163-Male,
pubmed-meshheading:2935163-Middle Aged,
pubmed-meshheading:2935163-Neomycin,
pubmed-meshheading:2935163-Niacin
|
pubmed:year |
1985
|
pubmed:articleTitle |
Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment.
|
pubmed:publicationType |
Journal Article
|